Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under Pre-Arranged Plan

Edwards Lifesciences Global President Larry L. Wood executed a pre-planned sale of 8,950 shares of common stock after exercising employee stock options.

Summary

• Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences Corp (EW), reported changes in his beneficial ownership.
• On June 16, 2025, Mr. Wood acquired 8,950 shares of common stock by exercising employee stock options at a price of $59.2567 per share.
• Concurrently, on June 16, 2025, he disposed of 8,950 shares of common stock at a weighted average sale price of $75.2255 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Mr. Wood directly beneficially owns 206,900.3913 shares of common stock and indirectly owns 148.1703 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine exercise and sale under a pre-arranged trading plan, indicating no new positive or negative information about the company.

Positives

• The insider realized a gain from exercising options and selling shares, indicating personal financial benefit.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a scheduled event rather than a reaction to new, undisclosed company information.

Negatives

• The sale of shares by an insider, even if pre-planned, can sometimes be perceived as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Risks

• No specific risks to the company or its operations are mentioned in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025."
• "This transaction was executed in multiple trades at prices ranging from $74.8901 to $75.4400. The price reported above reflects the weighted average sale price."
• "The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as the transaction is routine and pre-planned, not signaling new company information.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

Edwards Lifesciences, EW, Form 4, Insider transaction, Stock option exercise, Stock sale, Rule 10b5-1, Larry L. Wood, Beneficial ownership, Corporate governance